Oral Estradiol Non-Responder Profile: Who Doesn't Get Results and Why

Is There a Defined Non-Responder Profile?

The oral estradiol label does not identify who is likely to get inadequate symptom relief. It treats relief as something to titrate: a usual initial dose of 1 to 2 mg daily, adjusted as necessary to control presenting symptoms, with the maintenance dose set by titration and the regimen reassessed every 3 to 6 months [2]. Someone still symptomatic on a starting dose is within what the label anticipates, since it calls for dose adjustment.

For symptoms of vulvar and vaginal atrophy alone, the label says topical vaginal products should be considered when prescribing solely for that purpose [2].

Why the Oral Route Delivers Less Estradiol

Swallowed estradiol passes through the liver before reaching the bloodstream. The Climara patch label states that systemic availability of estradiol after transdermal use is about 20 times higher than after oral use, because there is no first-pass metabolism with a patch [1]. That is a comparison of routes; it does not show whether switching routes relieves persistent symptoms.

Which Drugs the Label Names

The oral estradiol label says estrogens are metabolized partly by CYP3A4, and that inducers such as St John's wort, phenobarbital, carbamazepine and rifampin may reduce plasma concentrations of estrogens, possibly decreasing therapeutic effects and/or changing the uterine bleeding profile [2]. Inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase concentrations and cause side effects [2].

Does Switching Routes Help, and What About Clot Risk?

A patch avoids first-pass metabolism, but no study cited here tests whether switching improves symptoms after oral tablets have fallen short. Observational studies found higher clot-risk estimates among current oral estrogen users than transdermal users. In the ESTHER case-control study (271 cases of first idiopathic venous thromboembolism, 610 matched controls) the adjusted odds ratio versus nonusers was 4.2 (95% CI 1.5 to 11.6) for oral estrogen and 0.9 (0.4 to 2.1) for transdermal [4]. A 2008 BMJ meta-analysis of eight observational studies and nine randomized trials reported pooled observational odds ratios in current users of 2.5 (1.9 to 3.4) for oral and 1.2 (0.9 to 1.7) for transdermal estrogen [5]. These are observational associations and cannot establish the effect of changing routes. The patch labels still carry clot warnings and contraindications [1].